WO2019031729A3 - Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis - Google Patents
Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis Download PDFInfo
- Publication number
- WO2019031729A3 WO2019031729A3 PCT/KR2018/008325 KR2018008325W WO2019031729A3 WO 2019031729 A3 WO2019031729 A3 WO 2019031729A3 KR 2018008325 W KR2018008325 W KR 2018008325W WO 2019031729 A3 WO2019031729 A3 WO 2019031729A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alcoholic
- simple steatosis
- composition
- stem cell
- alcoholic steatohepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a composition comprising a stem cell-derived exosome as an effective ingredient for preventing, relieving, alleviating, or treating non-alcoholic simple steatosis or non-alcoholic steatohepatitis. A composition of the present invention can prevent, relieve, alleviate, or treat non-alcoholic simple steatosis or non-alcoholic steatohepatitis by reducing or relieving fat accumulation or inflammation in hepatocytes or liver tissues, which acts as a cause of non-alcoholic simple steatosis or non-alcoholic steatohepatitis and by inducing the histological state of non-alcoholic simple steatosis or non-alcoholic steatohepatitis to moderate, improve, or change for the better.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170099328 | 2017-08-05 | ||
KR10-2017-0099328 | 2017-08-05 | ||
KR10-2017-0162555 | 2017-11-30 | ||
KR1020170162555A KR20190015063A (en) | 2017-08-05 | 2017-11-30 | A composition comprising an exosome and/or extracellular vesicle derived from stem cell as an active ingredient and its application for improving non-alcoholic simple steatosis or non-alcoholic steatohepatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019031729A2 WO2019031729A2 (en) | 2019-02-14 |
WO2019031729A3 true WO2019031729A3 (en) | 2019-05-16 |
Family
ID=65271734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/008325 WO2019031729A2 (en) | 2017-08-05 | 2018-07-24 | Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019031729A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022544698A (en) * | 2019-08-22 | 2022-10-20 | プレクソジェン インコーポレイテッド | Composition for prevention or treatment of non-alcoholic steatohepatitis containing exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell progenitor cells |
US20230115023A1 (en) * | 2021-10-07 | 2023-04-13 | China Medical University | Use of exosomes derived from mesenchymal stem cells fortreating non-alcoholic steatohepatitis |
CN115386543B (en) * | 2022-07-19 | 2024-02-02 | 长春科技学院 | Pilose antler stem cell exosome and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101501433B1 (en) * | 2014-06-10 | 2015-03-11 | 주식회사 머쉬메드 | A composition for prevention and treatment of non-alcoholic fatty liver disease |
WO2016054094A1 (en) * | 2014-09-30 | 2016-04-07 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating hepatic fibrosis |
CN106974937A (en) * | 2017-03-30 | 2017-07-25 | 山东大学 | Application of the adipose-derived mescenchymal stem cell excretion body in treatment metabolic syndrome medicine is prepared |
-
2018
- 2018-07-24 WO PCT/KR2018/008325 patent/WO2019031729A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101501433B1 (en) * | 2014-06-10 | 2015-03-11 | 주식회사 머쉬메드 | A composition for prevention and treatment of non-alcoholic fatty liver disease |
WO2016054094A1 (en) * | 2014-09-30 | 2016-04-07 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating hepatic fibrosis |
CN106974937A (en) * | 2017-03-30 | 2017-07-25 | 山东大学 | Application of the adipose-derived mescenchymal stem cell excretion body in treatment metabolic syndrome medicine is prepared |
Non-Patent Citations (2)
Title |
---|
HU , LI ET AL.: "Exosomes Derived from Human Adipose Mensenchymal Stem Cells Accelerates Cutaneous Wound Healing via Optimizing the Characteristics of Fibroblasts", SCIENTIFIC REPORTS, vol. 6, 2016, pages 1 - 1 1, XP055485849, DOI: doi:10.1038/srep32993 * |
LEE, YOUNG-SUN ET AL.: "Exosomes Derived from Palmitic Acid-treated Hepatocytes Induce Fibrotic Activation of Hepatic Stellate Cells", SCIENTIFIC REPORTS, vol. 7, no. 1, 16 June 2017 (2017-06-16), pages 1 - 10, XP055608796, ISSN: 2045-2322, DOI: 10.1038/s41598-017-03389-2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019031729A2 (en) | 2019-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220245A1 (en) | Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders | |
PH12021550985A1 (en) | Vesicles derived from lactobacillus paracasei and use of same | |
EP3639832A4 (en) | Use of composition comprising adipose stem cell-derived exosome as effective ingredient in alleviating dermatitis | |
WO2019031729A3 (en) | Use of composition comprising stem cell-derived exosome as effective ingredient in alleviating non-alcoholic simple steatosis or non-alcoholic steatohepatitis | |
MX2021010350A (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising leuconostoc citreum wikim0104. | |
WO2019004757A3 (en) | Use of composition comprising stem cell-derived exosome as effective ingredient for prevention or alleviation of pruritus | |
PH12017500706A1 (en) | Composition containing extract or fraction of genus justicia plant | |
WO2019045287A3 (en) | Composition comprising fraction of rosa multiflora extract as effective ingredient for preventing, alleviating, or treating immune disease | |
MX2021010349A (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103. | |
EP3817749A4 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
ZA201901367B (en) | Inhibition of olig2 activity | |
WO2017019721A3 (en) | Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer | |
EP4041209A4 (en) | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders | |
PH12017502081A1 (en) | Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
EP3773466A4 (en) | Topical composition comprised of cod liver oil for treating wounds and skin disorders | |
WO2019004738A3 (en) | Use of composition comprising adipose stem cell-derived exosome as effective ingredient in alleviating dermatitis | |
MX2020008991A (en) | Methods for altering body composition. | |
WO2018074862A3 (en) | Pharmaceutical composition comprising tha as active ingredient for treating breast cancer | |
MX2019010218A (en) | Pyrazole derivatives as bromodomain inhibitors. | |
MX2021006605A (en) | Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis. | |
EP3737384A4 (en) | Methods and compositions for preventing and treating conditions related to alpha-synuclein | |
EP3727397A4 (en) | Composition and method for treating, relieving or preventing neuropathic pain, containing choline alfoscerate as active ingredient | |
EP3833341A4 (en) | Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure | |
MX2019000006A (en) | Compositions for the treatment of ischemic ulcers and stretch marks. | |
EP3881854A4 (en) | Composition comprising plant extract of genus fraxinus as active ingredient for preventing, alleviating, or treating sleep disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18843917 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18843917 Country of ref document: EP Kind code of ref document: A2 |